Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results. See why I remain bullish on TEM stock.

For the full year, the Data and Services division was a key contributor. The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a ...

Tempus announced its acquisition of Ambry Genetics for $375 million in cash and $225 million in shares at closing in November and the deal closed earlier this month. Ambry will continue to operate ...

Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which included $375 million in cash ...

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics and personalized treatments. Read more here.

The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics (“Ambry”), which closed on February 3, 2025. Combined with $260 million of capital provided in ...

Cathie Wood’s ARK Investment continues to capitalize on the pullback in Tempus AI (TEM) stock by accumulating more shares, ...

A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financia ...

Acquisition: Closed the acquisition of Ambry Genetics on February 3. Google Agreement: Extended for another five years. Tempus AI Inc (NASDAQ:TEM) reported a 35.8% year-over-year revenue growth in ...

The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a West Coast lab and expanding inherited risk testing. Another ...